Eleven months on from the initial outbreak of COVID-19 in China, the virus continues to be a hot topic around the world, generating vast interest due to the impact on personal freedom, finances, and health. To better understand the impact of the pandemic on different countries, we have previously published two reports:
The November report provides a number of key insights, but one theme that particulary stands out is the different investment strategies for the vaccines being developed. There are currently more than 100 COVID-19 vaccines in development (48 in clinical evaluation, 164 in preclinical evaluation), with three of those close to receiving market authorisation by the main regulatory agencies across the world. From the vast media coverage of these three vaccines, it will be no surprise that these include the AstraZeneca/Oxford vaccine, Pfizer/BioNTech vaccine, and the Moderna vaccine. The three vaccines all require 2 doses but differ from the perspective of production methods, storage requirements, efficacy and cost per dose (ranging from $3 to $37 per dose). Here is a quick summary of the differences and published investment plans for the three 'first to market' (excluding Russia and China) vaccines in development:
Further information on the various insights emerging from COVID-19 as of November 2020, are summarised in our latest report. The November report provides an overview from a range of markets:
If you would like a copy of this report, or any of our previous reports, please contact firstname.lastname@example.org or fill out the contact form for one of the FingerPost team to follow up.